Life Science Investing ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
Life Science Investing neffy® Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions
Life Science Investing Real-World Evidence Supports Clinical Effectiveness of neffy® in Patients Experiencing Anaphylaxis
Life Science Investing ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy®
